BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25400827)

  • 1. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.
    Lu W; Xu Z; Zhang M; Zuo Y
    Int J Clin Exp Pathol; 2014; 7(10):7286-96. PubMed ID: 25400827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.
    Lu WD; Zuo Y; Xu Z; Zhang M
    World J Gastroenterol; 2015 Apr; 21(15):4564-73. PubMed ID: 25914465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway.
    Song SZ; Lin S; Liu JN; Zhang MB; Du YT; Zhang DD; Xu WH; Wang HB
    J Cell Physiol; 2019 Aug; 234(10):18587-18601. PubMed ID: 30953349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways.
    Ha GH; Park JS; Breuer EK
    Cancer Lett; 2013 May; 332(1):63-73. PubMed ID: 23348690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2.
    He Y; Ge Y; Jiang M; Zhou J; Luo D; Fan H; Shi L; Lin L; Yang L
    Cell Physiol Biochem; 2018; 47(4):1465-1481. PubMed ID: 29949784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.
    Zhang P; Tang WM; Zhang H; Li YQ; Peng Y; Wang J; Liu GN; Huang XT; Zhao JJ; Li G; Li AM; Bai Y; Chen Y; Ren YX; Li GX; Wang YD; Liu SD; Wang JD
    Br J Cancer; 2017 Aug; 117(4):525-534. PubMed ID: 28632723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.
    Huang N; Wu Z; Lin L; Zhou M; Wang L; Ma H; Xia J; Bin J; Liao Y; Liao W
    Oncotarget; 2015 Jun; 6(17):15222-34. PubMed ID: 25945841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
    Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
    Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer.
    Liu Z; Zhu J; Cao H; Ren H; Fang X
    Int J Oncol; 2012 May; 40(5):1553-60. PubMed ID: 22293682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-379 inhibits metastasis and epithelial-mesenchymal transition via targeting FAK/AKT signaling in gastric cancer.
    Xu M; Qin S; Cao F; Ding S; Li M
    Int J Oncol; 2017 Sep; 51(3):867-876. PubMed ID: 28713929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-181d inhibits cell proliferation and metastasis through PI3K/AKT pathway in gastric cancer.
    Jiang K; Xie LF; Xiao TZ; Qiu MY; Wang WL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8861-8869. PubMed ID: 31696473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling.
    Zheng YB; Xiao GC; Tong SL; Ding Y; Wang QS; Li SB; Hao ZN
    World J Gastroenterol; 2015 Jun; 21(23):7197-207. PubMed ID: 26109806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
    Sun C; Tao Y; Gao Y; Xia Y; Liu Y; Wang G; Gu Y
    Biomed Pharmacother; 2018 Feb; 98():416-423. PubMed ID: 29278851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway.
    Cheng Y; Li Y; Liu D; Zhang R; Zhang J
    FEBS Lett; 2014 Aug; 588(17):3274-81. PubMed ID: 25064845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling.
    Xu SH; Huang JZ; Xu ML; Yu G; Yin XF; Chen D; Yan GR
    J Pathol; 2015 Jun; 236(2):175-85. PubMed ID: 25678401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-107 regulates growth and metastasis of gastric cancer cells via activation of the PI3K-AKT signaling pathway by down-regulating FAT4.
    Wang L; Li K; Wang C; Shi X; Yang H
    Cancer Med; 2019 Sep; 8(11):5264-5273. PubMed ID: 31297980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling.
    Li F; Yin X; Luo X; Li HY; Su X; Wang XY; Chen L; Zheng K; Ren GS
    Cell Signal; 2013 Jun; 25(6):1413-22. PubMed ID: 23524337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
    Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J
    Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRP4 promotes migration and invasion of gastric cancer under the regulation of microRNA-140-5p.
    Mao Z; Wang Z; Zhang S; Pu Y; Wang J; Zhang T; Long Y; Liu Y; Ma Y; Zhu J
    Cancer Biomark; 2020; 29(2):245-253. PubMed ID: 32675391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.